Compare McKesson Corporation (MCK) vs Weibo Corp (WB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McKesson Corporation vs Weibo Corp — how do they compare? McKesson Corporation trades at $930 (market cap $108.46B), while Weibo Corp trades at $6.46 (market cap $1.56B). The key difference: McKesson Corporation is far larger — about 69.5× Weibo Corp's market cap, and Weibo Corp pays the higher dividend (9.47%). Which is the better fit depends on your goals — on Pluang, investors hold McKesson Corporation for 74 Days and Weibo Corp for 102 Days on average.
| MCK | WB | |
|---|---|---|
Market Cap | $108.46B | $1.56B |
Volume | 712,607 | 812,503 |
Sector | Health | Media |
52-Week High | $995.69 | $12.37 |
52-Week Low | $725.17 | $6.33 |
Typical Hold Time | 74 Days | 102 Days |
Enterprise Value | $115.00B | $786.69M |
Dividend Yield | 0.4% | 9.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
McKesson Corporation (MCK) trades at $910.33, down 1.23% today, but maintains strong analyst support with 80.65% buy ratings and a $956.43 consensus price target. The stock shows bullish technical momentum with recent earnings beats and a major distribution agreement extension with CVS Health through 2032. Revenue growth has accelerated from $264B in 2022 to $359B in 2025, though net margins remain thin at 1.12%.
MCK presents a compelling growth story with consistent earnings outperformance and strategic partnerships driving long-term visibility. However, investors face risks from margin compression, drug pricing pressures, and high leverage with negative shareholder equity. The current valuation at 24.42x P/E appears reasonable given the company's market leadership and oncology growth prospects.
Weibo (WB) trades at $6.48, down 0.15% with bearish technical signals. The stock shows attractive valuation metrics including a P/E of 5.36 and P/B of 0.4, while maintaining strong profitability with 73.36% gross margins. Recent earnings show mixed performance with Q2 2026 beating expectations but Q4 2025 and Q1 2026 missing estimates. Cash flow trends indicate volatility with a significant net outflow in 2024 followed by recovery in 2025.
Weibo presents as a deep-value opportunity with compelling valuation multiples, though growth concerns persist amid declining user metrics and advertising challenges. Analyst sentiment remains divided with 40.9% buy ratings versus 45.5% hold, reflecting uncertainty about the company's ability to maintain relevance against intensifying competition in social media.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →About Weibo Corp
Weibo is the largest social media platform in China. As of 2020, Weibo had 521 million monthly active users and 225 million daily active users, many of whom are drawn there by the millions of key opinion leaders in entertainment, sports, and business circles. Sina is the major shareholder, holding 44.7% of shares and with 70.8% voting power.
Read more on WB →
